secwatch.observer — SEC 8-K summary
======================================

Issuer:     Forte Biosciences, Inc. (FBRX)
CIK:        0001419041
Form:       8-K
Filed at:   2024-03-18T23:59:59+00:00
Accession:  0001193125-24-070158
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Forte Biosciences reports FY 2023 net loss of $31.5M; FB-102 advances to MAD cohort
--------------------------------------------------------------------------------

- Net loss of $31.5M ($1.00 per share) vs. $13.9M ($0.80) in FY 2022, driven by increased R&D spend.
- R&D expenses rose to $21.9M from $5.6M, primarily due to FB-102 manufacturing and clinical costs.
- Cash and equivalents of $37.1M at year-end 2023, down from $41.1M at end of 2022.
- FB-102 Phase 1 SAD portion completed; multiple ascending dose (MAD) cohorts now dosing.
- Shares outstanding of 36.3M as of Dec 31, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1419041/000119312524070158/0001193125-24-070158-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1419041/000119312524070158/d784785d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-070158

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer